CAR19-T cell approach was tried in a group of 9 RT patients who were heavily pre-treated with CIT, BTK inhibitor with or without BCL-2 inhibitor in CLL phase followed by R-CHOP for RT phase. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.